Bristol Myers Squibb Co. on Wednesday said its third-quarter sales rose 10 percent and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year. The New York-based drugmaker’s revenue for the quarter of $11.6 billion and adjusted profit of $2.00 per share both topped Wall Street estimates of $11.58 billion in sales and $1.92 per share, according to IBES data from Refinitiv. Bristol Myers raised the low end of its full-year adjusted profit forecast by 5 cents and now expects to earn $7.40 to $7.55 per share. Bristol Myers had missed analysts’ estimates in the first quarter, largely due to a decline in sales of its growth driver, the cancer immunotherapy Opdivo. Sales growth has since recovered. “We’re seeing good recovery from COVID really across all of our markets,” Chris Boerner, Bristol Myers’ chief commercialization officer, said in an interview. “In immuno-oncology, we’ve seen …